Welcome to our dedicated page for Vyne Therapeutics SEC filings (Ticker: VYNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
VYNE Therapeutics Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company developing BET inhibitor therapies for inflammatory and immune-mediated conditions. Form 8-K disclosures include quarterly results, clinical and regulatory updates for Repibresib gel and VYN202, and capital-structure information for VYNE common stock.
The filing record also covers stockholder meeting results, director and governance matters, material-event reports, registered security information, and Nasdaq continued-listing compliance disclosures, including minimum bid price notices and extension communications.